First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
- Martin Schuler
- , Luis Paz-Ares
- , Lecia V. Sequist
- , Vera Hirsh
- , Ki Hyeong Lee
- , Yi Long Wu
- , Shun Lu
- , Caicun Zhou
- , Jifeng Feng
- , Stuart H. Ellis
- , Carl H. Samuelsen
- , Wenbo Tang
- , Angela Märten
- , Eva Ehrnrooth
- , Keunchil Park
- , James Chih Hsin Yang
- University of Duisburg-Essen
- Hospital Universitario 12 de Octubre
- Massachusetts General Hospital
- McGill University
- Chungbuk National University
- Guangdong Academy of Medical Sciences
- Shanghai Jiao Tong University
- Tongji University
- Jiangsu Provincial Tumor Hospital
- Independent Statistical Consultant
- Boehringer Ingelheim GmbH
- Boehringer Ingelheim
- National Taiwan University
Research output: Contribution to journal › Article › peer-review
30
Link opens in a new tab
Scopus
citations